Strategic collaboration with leading global manufacturer of drug delivery systems strengthens NS002's clinical and commercial roadmap with end-to-end development support and manufacturing infrastructureTEL AVIV, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) (“Nasus Pharma” or the “Company”), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products to treat emergency medical conditions, today announced the execution of comprehensive agreements wi ...

Core Insights - Nasus Pharma Ltd. has entered into comprehensive agreements with Aptar France S.A.S. and AptarGroup, Inc. to support the clinical development and commercialization of its intranasal powder epinephrine product candidate, NS002 [1][2] - The collaboration is expected to provide Nasus Pharma with a validated dosing infrastructure and access to Aptar's technical expertise, which will help accelerate NS002's path to market while reducing development risks [2] Company Overview - Nasus Pharma is a clinical-stage pharmaceutical company focused on developing intranasal powder products for acute medical conditions, with NS002 being a needle-free alternative to epinephrine autoinjectors for anaphylaxis [3] - The company's proprietary powder-based intranasal (PBI) technology is designed for rapid drug delivery, utilizing the nasal cavity's vascular network for quick absorption, and aims to offer potentially faster and higher absorption compared to liquid-based nasal products [3]

A NEW FRONTIER FOR INTRANASAL DRUG DELIVERY Company Presentation – August 2025 A clinical-stage pharmaceutical company leveraging its proprietary powder-based intranasal technology to develop innovative intranasal products to treat emergency medical conditions Ticker NSRX Exchange NYSE American 1 Experienced leadership team Strong IP protection to 2038 Forward Looking Statements This presentation of Nasus Pharma Ltd. contains "forward-looking statements" within the meaning of the Private Securities Litigati ...